{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:46:58Z","timestamp":1761630418095},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The IFN-\u03b3 ELISPOT assay has been used to examine the T-cell repertoire for many disease states in humans but, as yet, not genital herpes. Using overlapping synthetic peptide libraries, an IFN-\u03b3 ELISPOT assay was established that could measure CD4 and CD8 T-cell responses to HSV-2 antigens in patients with genital herpes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In unexpanded T-cells isolated from peripheral blood, CD4 responses were readily measured against four immediate early antigens (ICP0, ICP4, ICP22 and ICP27), VP22 and gD. The CD4 responses were characterized by a low number of positive cells which produced large ELISPOTs. CD4 responses had a broad specificity and within individual patients several of the test antigens were recognized. In contrast, CD8 responses were found only in approximately 50% of patients and were typically specific to a single antigen. When disease status and immune responses were compared, an enhanced CD4 response to ICP4 in patients with a low recurrence rate was found. The ICP4 response was striking in three HSV-1 single positive genital herpes patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The survey of T-cell responses is an important step to understand the host cellular immune response in individuals with genital herpes. The assay described here has the capability of measuring CD4 and CD8 T-cell responses that may be used to correlate disease status with specific immune responses. In an evaluation of 18 subjects a trend of positive responses to an immediate early protein, ICP4, was found in individuals that had a low rate of disease recurrence.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1743-422x-3-54","type":"journal-article","created":{"date-parts":[[2006,8,8]],"date-time":"2006-08-08T21:36:37Z","timestamp":1155072997000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characterization of the IFN-\u03b3 T-cell responses to immediate early antigens in humans with genital herpes"],"prefix":"10.1186","volume":"3","author":[{"given":"Ralph P","family":"Braun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lendon G","family":"Payne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lichun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,7,5]]},"reference":[{"key":"161_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00007435-200001000-00007","volume":"27","author":"G Tao","year":"2000","unstructured":"Tao G, Kassler WJ, Rein DB: Medical care expenditures for genital herpes in the United States. Sex Transm Dis 2000, 27: 32-38.","journal-title":"Sex Transm Dis"},{"key":"161_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00003226-200101000-00001","volume":"20","author":"TJ Liesegang","year":"2001","unstructured":"Liesegang TJ: Herpes simplex virus epidemiology and ocular importance. Cornea 2001, 20: 1-13. 10.1097\/00003226-200101000-00001","journal-title":"Cornea"},{"key":"161_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/sti.2004.009753","volume":"80","author":"T Tran","year":"2004","unstructured":"Tran T, Druce JD, Catton MC, Kelly H, Birch CJ: Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect 2004, 80: 277-279. 10.1136\/sti.2004.009753","journal-title":"Sex Transm Infect"},{"key":"161_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/01.OLQ.0000092387.58746.C7","volume":"30","author":"CM Roberts","year":"2003","unstructured":"Roberts CM, Pfister JR, Spear SJ: Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003, 30: 797-800.","journal-title":"Sex Transm Dis"},{"key":"161_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/10454411980090040901","volume":"9","author":"CS Miller","year":"1998","unstructured":"Miller CS, Danaher RJ, Jacob RJ: Molecular aspects of herpes simplex virus I latency, reactivation, and recurrence. Crit Rev Oral Biol Med 1998, 9: 541-562.","journal-title":"Crit Rev Oral Biol Med"},{"key":"161_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1086\/313687","volume":"30","author":"LR Stanberry","year":"2000","unstructured":"Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, Lacey CJ: Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000, 30: 549-566. 10.1086\/313687","journal-title":"Clin Infect Dis"},{"key":"161_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1128\/CMR.16.1.96-113.2003","volume":"16","author":"DM Koelle","year":"2003","unstructured":"Koelle DM, Corey L: Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003, 16: 96-113. 10.1128\/CMR.16.1.96-113.2003","journal-title":"Clin Microbiol Rev"},{"key":"161_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jri.2003.12.002","volume":"61","author":"GN Milligan","year":"2004","unstructured":"Milligan GN, Dudley-McClain KL, Young CG, Chu CF: T-cell-mediated mechanisms involved in resolution of genital herpes simplex virus type 2 (HSV-2) infection of mice. J Reprod Immunol 2004, 61: 115-127. 10.1016\/j.jri.2003.12.002","journal-title":"J Reprod Immunol"},{"key":"161_CR9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1286-4579(00)00339-7","volume":"2","author":"SP Deshpande","year":"2000","unstructured":"Deshpande SP, Kumaraguru U, Rouse BT: Why do we lack an effective vaccine against herpes simplex virus infections? Microbes Infect 2000, 2: 973-978. 10.1016\/S1286-4579(00)00339-7","journal-title":"Microbes Infect"},{"key":"161_CR10","doi-asserted-by":"publisher","first-page":"10289","DOI":"10.1073\/pnas.94.19.10289","volume":"94","author":"CM Posavad","year":"1997","unstructured":"Posavad CM, Koelle DM, Shaughnessy MF, Corey L: Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 1997, 94: 10289-10294. 10.1073\/pnas.94.19.10289","journal-title":"Proc Natl Acad Sci U S A"},{"key":"161_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.coi.2004.05.003","volume":"16","author":"KM Khanna","year":"2004","unstructured":"Khanna KM, Lepisto AJ, Decman V, Hendricks RL: Immune control of herpes simplex virus during latency. Curr Opin Immunol 2004, 16: 463-469. 10.1016\/j.coi.2004.05.003","journal-title":"Curr Opin Immunol"},{"key":"161_CR12","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.4049\/jimmunol.166.6.4049","volume":"166","author":"DM Koelle","year":"2001","unstructured":"Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, Corey L: CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol 2001, 166: 4049-4058.","journal-title":"J Immunol"},{"key":"161_CR13","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1128\/jvi.68.5.2803-2810.1994","volume":"68","author":"DM Koelle","year":"1994","unstructured":"Koelle DM, Corey L, Burke RL, Eisenberg RJ, Cohen GH, Pichyangkura R, Triezenberg SJ: Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 1994, 68: 2803-2810.","journal-title":"J Virol"},{"key":"161_CR14","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.4049\/jimmunol.164.10.5167","volume":"164","author":"Z Mikloska","year":"2000","unstructured":"Mikloska Z, Ruckholdt M, Ghadiminejad I, Dunckley H, Denis M, Cunningham AL: Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol 2000, 164: 5167-5176.","journal-title":"J Immunol"},{"key":"161_CR15","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.4049\/jimmunol.156.10.3901","volume":"156","author":"MA Tigges","year":"1996","unstructured":"Tigges MA, Leng S, Johnson DC, Burke RL: Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J Immunol 1996, 156: 3901-3910.","journal-title":"J Immunol"},{"key":"161_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00002371-200203000-00001","volume":"25","author":"U Keilholz","year":"2002","unstructured":"Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25: 97-138. 10.1097\/00002371-200203000-00001","journal-title":"J Immunother"},{"key":"161_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0022-1759(01)00397-0","volume":"254","author":"TW Tobery","year":"2001","unstructured":"Tobery TW, Wang S, Wang XM, Neeper MP, Jansen KU, McClements WL, Caulfield MJ: A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. J Immunol Methods 2001, 254: 59-66. 10.1016\/S0022-1759(01)00397-0","journal-title":"J Immunol Methods"},{"key":"161_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/viro.1997.8441","volume":"229","author":"GN Milligan","year":"1997","unstructured":"Milligan GN, Bernstein DI: Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 1997, 229: 259-268. 10.1006\/viro.1997.8441","journal-title":"Virology"},{"key":"161_CR19","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1128\/JVI.75.22.11178-11184.2001","volume":"75","author":"T Liu","year":"2001","unstructured":"Liu T, Khanna KM, Carriere BN, Hendricks RL: Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol 2001, 75: 11178-11184. 10.1128\/JVI.75.22.11178-11184.2001","journal-title":"J Virol"},{"key":"161_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1074-7613(03)00112-2","volume":"18","author":"KM Khanna","year":"2003","unstructured":"Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL: Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003, 18: 593-603. 10.1016\/S1074-7613(03)00112-2","journal-title":"Immunity"},{"key":"161_CR21","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1084\/jem.191.9.1459","volume":"191","author":"T Liu","year":"2000","unstructured":"Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL: CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 2000, 191: 1459-1466. 10.1084\/jem.191.9.1459","journal-title":"J Exp Med"},{"key":"161_CR22","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.1128\/JVI.72.9.7476-7483.1998","volume":"72","author":"DM Koelle","year":"1998","unstructured":"Koelle DM, Frank JM, Johnson ML, Kwok WW: Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol 1998, 72: 7476-7483.","journal-title":"J Virol"},{"key":"161_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/0264-410X(94)90195-3","volume":"12","author":"NE Byars","year":"1994","unstructured":"Byars NE, Fraser-Smith EB, Pecyk RA, Welch M, Nakano G, Burke RL, Hayward AR, Allison AC: Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine 1994, 12: 200-209. 10.1016\/0264-410X(94)90195-3","journal-title":"Vaccine"},{"key":"161_CR24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1128\/jvi.56.3.1014-1017.1985","volume":"56","author":"RJ Eisenberg","year":"1985","unstructured":"Eisenberg RJ, Cerini CP, Heilman CJ, Joseph AD, Dietzschold B, Golub E, Long D, Ponce de Leon M, Cohen GH: Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge. J Virol 1985, 56: 1014-1017.","journal-title":"J Virol"},{"key":"161_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev.iy.11.040193.001241","volume":"11","author":"HG Rammensee","year":"1993","unstructured":"Rammensee HG, Falk K, Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993, 11: 213-244. 10.1146\/annurev.iy.11.040193.001241","journal-title":"Annu Rev Immunol"},{"key":"161_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0022-1759(01)00535-X","volume":"260","author":"JR Currier","year":"2002","unstructured":"Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH: A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002, 260: 157-172. 10.1016\/S0022-1759(01)00535-X","journal-title":"J Immunol Methods"},{"key":"161_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/sti.2004.012039","volume":"81","author":"KJ Looker","year":"2005","unstructured":"Looker KJ, Garnett GP: A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect 2005, 81: 103-107. 10.1136\/sti.2004.012039","journal-title":"Sex Transm Infect"},{"key":"161_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.282.4.331","volume":"282","author":"L Corey","year":"1999","unstructured":"Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JMJ, Handsfield HH, Warren T, Marr L, Tyring S, DiCarlo R, Adimora AA, Leone P, Dekker CL, Burke RL, Leong WP, Straus SE: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Jama 1999, 282: 331-340. 10.1001\/jama.282.4.331","journal-title":"Jama"},{"key":"161_CR29","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1086\/429240","volume":"40","author":"DI Bernstein","year":"2005","unstructured":"Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, Leroux-Roels G, Van Herck K, Bollaerts A, Dubin G: Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005, 40: 1271-1281. 10.1086\/429240","journal-title":"Clin Infect Dis"},{"key":"161_CR30","doi-asserted-by":"publisher","first-page":"12899","DOI":"10.1073\/pnas.2131705100","volume":"100","author":"DM Koelle","year":"2003","unstructured":"Koelle DM, Liu Z, McClurkan CL, Cevallos RC, Vieira J, Hosken NA, Meseda CA, Snow DC, Wald A, Corey L: Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A 2003, 100: 12899-12904. 10.1073\/pnas.2131705100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"161_CR31","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1084\/jem.175.5.1337","volume":"175","author":"A Simmons","year":"1992","unstructured":"Simmons A, Tscharke DC: Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med 1992, 175: 1337-1344. 10.1084\/jem.175.5.1337","journal-title":"J Exp Med"},{"key":"161_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1172\/JCI0215537","volume":"110","author":"DM Koelle","year":"2002","unstructured":"Koelle DM, Liu Z, McClurkan CM, Topp MS, Riddell SR, Pamer EG, Johnson AS, Wald A, Corey L: Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest 2002, 110: 537-548. 10.1172\/JCI200215537","journal-title":"J Clin Invest"},{"key":"161_CR33","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/S0002-9440(10)63575-4","volume":"163","author":"D Theil","year":"2003","unstructured":"Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O, Strupp M, Arbusow V, Brandt T: Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003, 163: 2179-2184.","journal-title":"Am J Pathol"},{"key":"161_CR34","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1073\/pnas.022301899","volume":"99","author":"LT Feldman","year":"2002","unstructured":"Feldman LT, Ellison AR, Voytek CC, Yang L, Krause P, Margolis TP: Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci U S A 2002, 99: 978-983. 10.1073\/pnas.022301899","journal-title":"Proc Natl Acad Sci U S A"},{"key":"161_CR35","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1128\/jvi.67.10.6259-6264.1993","volume":"67","author":"M Yasukawa","year":"1993","unstructured":"Yasukawa M, Yakushijin Y, Furukawa M, Fujita S: Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus. J Virol 1993, 67: 6259-6264.","journal-title":"J Virol"},{"key":"161_CR36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1099\/0022-1317-79-2-353","volume":"79 ( Pt 2)","author":"Z Mikloska","year":"1998","unstructured":"Mikloska Z, Cunningham AL: Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 1998, 79 ( Pt 2): 353-361.","journal-title":"J Gen Virol"},{"key":"161_CR37","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1172\/JCI1758","volume":"101","author":"DM Koelle","year":"1998","unstructured":"Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L: Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998, 101: 1500-1508.","journal-title":"J Clin Invest"},{"key":"161_CR38","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1128\/JVI.76.9.4536-4546.2002","volume":"76","author":"J Arrington","year":"2002","unstructured":"Arrington J, Braun RP, Dong L, Fuller DH, Macklin MD, Umlauf SW, Wagner SJ, Wu MS, Payne LG, Haynes JR: Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol 2002, 76: 4536-4546. 10.1128\/JVI.76.9.4536-4546.2002","journal-title":"J Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-3-54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T12:39:17Z","timestamp":1683549557000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-3-54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-3-54","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,5]]},"assertion":[{"value":"23 February 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"54"}}